Napredna pretraga

Pregled bibliografske jedinice broj: 670480

Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria


Petrosillo, N. ...; Baršić, Bruno; Belančić, L.; ...; Akova, M.
Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria // Antimicrobial agents and chemotherapy, 58 (2014), 2; 851-858 doi:10.1128/AAC.00871-13 (međunarodna recenzija, članak, znanstveni)


Naslov
Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria

Autori
Petrosillo, N. ... ; Baršić, Bruno ; Belančić, L. ; ... ; Akova, M.

Izvornik
Antimicrobial agents and chemotherapy (0066-4804) 58 (2014), 2; 851-858

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Colistin; vancomycin; MRSA

Sažetak
Colistin-glycopeptide combination (CGC) has been shown in vitro to be synergistic against multi-drug-resistant Gram negative bacteria (MDR-GNB), specially Acinetobacter baumannii, and to prevent further resistance. However, clinical data are lacking.We carried out a retrospective multicenter study of patients hospitalized in Intensive Care Units (ICUs) who received colistin for GNB infection over 1-year period, to assess the rates of nephrotoxicity and 30-day mortality, after treatment onset, among patients treated with and without CGC for ≥ 48 hours.Of the 184 patients treated with colistin, GNB infection was documented in 166. The main causative agents were: MDR A. baumannii (59.6%), MDR Pseudomonas aeruginosa (18.7%) and carbapenem-resistant Klebsiella pneumoniae (14.5%) ; in 16.9% of patients Gram positive bacteria (GPB) co-infection was documented. Overall, 68 patients (40.9%) received CGC. Comparison of patients treated with and without CGC showed significant differences for respiratory failure (39.7% vs. 58.2%), ventilator associated pneumonia (54.4% vs. 71.4%), MDR A. baumannii (70.6% vs. 52%) and GPB co-infection (41.2% vs. 0) ; there were no differences for nephrotoxicity (11.8% vs. 13.3%) and 30-day mortality (33.8% and 29.6%). Cox analysis, performed on patients who survived ≥ 5 days after treatment onset, showed Charlson index (HR 1.26, 95%CI 1.01-1.44, p=0.001) and MDR A. baumannii (HR 2.51, 95%CI 1.23-5.12, p=0.01) as independent predictors of 30-day mortality, whereas receiving CGC for ≥ 5 days was a protective factor (HR 0.42, 95%CI 0.19-0.93, p=0.03).We found that CGC was not associated with higher nephrotoxicity and was a protective factor for mortality if administered for ≥ 5 days.

Izvorni jezik
Engleski



POVEZANOST RADA


Projekt / tema
108-1080002-0102 - Procjena potrebe i učinkovitosti liječenja teških infekcija u JIM (Bruno Baršić, )

Ustanove
Medicinski fakultet, Zagreb

Autor s matičnim brojem:
Bruno Baršić, (96532)

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati